PRTK Paratek Pharmaceuticals Inc.

-0.25  -4%
Previous Close 6.26
Open 6.23
Price To Book 3.36
Market Cap 193167272
Shares 32,140,977
Volume 634,836
Short Ratio
Av. Daily Volume 855,487

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Community-acquired bacterial pneumonia (CABP)
FDA Approval announced October 2, 2018.
Severe acne vulgaris
Phase 2 data due 2H 2019.
Urinary tract infections
Phase 2 dosing announced November 27, 2018 with data due 2H 2019.
Complicated urinary tract infections (cUTI)

Latest News

  1. Arbiter Partners Capital Management’s Returns, AUM and Holdings
  2. Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK)
  3. Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc — Research Highlights Growth, Revenue, and Consolidated Results
  4. Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
  5. Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
  6. Edited Transcript of PRTK earnings conference call or presentation 6-Nov-18 9:30pm GMT
  7. Do Institutions Own Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Shares?
  8. Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Misses Revenue Estimates
  9. Paratek: 3Q Earnings Snapshot
  10. Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
  11. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  12. Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
  13. Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence
  14. War against the superbugs: Mass. biotechs step up to fight antibiotic resistance
  15. 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout
  16. Major Action in Biotech and This is The Next Winner
  17. Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today
  18. Paratek Pharmaceuticals (PRTK) in Focus: Stock Moves 8.7% Higher

SEC Filings

  1. 8-K - Current report 181214432
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 181178349
  3. S-8 - Securities to be offered to employees in employee benefit plans 181164033
  4. 8-K - Current report 181162977
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181162936
  6. 8-K - Current report 181133880
  7. 8-K - Current report 181128591
  8. 8-K - Current report 181108066
  9. 8-K - Current report 181103096
  10. CT ORDER - Confidential treatment order 181027395